Neurodegenerative and autoimmune disorders

Annexon Inc. is pioneering innovative therapies targeting the classical complement pathway, specifically focusing on the inhibition of C1q, the initiating molecule of this pathway. By blocking C1q, Annexon aims to prevent the downstream activation of inflammatory components that contribute to tissue damage and disability in various complement-mediated diseases. Their approach is designed to address a range of serious conditions, including autoimmune disorders, neurodegenerative diseases, and ophthalmic diseases, by stopping the complement cascade at its source. This strategy is particularly relevant for conditions like Guillain-Barré syndrome, Huntington's disease, and geographic atrophy, where C1q plays a critical role in disease progression.

The company's clinical pipeline includes several investigational monoclonal antibodies, such as ANX005, which is being developed for Guillain-Barré syndrome and has received Fast Track and Orphan Drug designations from regulatory authorities. Other candidates, like ANX007 and ANX1502, target geographic atrophy and autoimmune diseases, respectively, showcasing Annexon's commitment to developing therapies that can benefit both rare and larger patient populations. By focusing on the early intervention of complement-mediated diseases, Annexon aims to deliver transformative treatments that can significantly improve patient outcomes across multiple therapeutic areas.

United States

Annexon Biosciences is a clinical-stage biopharmaceutical company developing novel therapies for autoimmune and neurodegenerative diseases, including ophthalmic diseases.

Eye Diseases

Genetic Diseases

Immune System Diseases

Nervous System Diseases

Pathological Conditions

Urogenital Diseases

Annexon Inc.

Autoimmune disease

Guillian-Barre syndrome

ANX005 is a clinical-stage investigational monoclonal antibody intended to treat patients with antibody-mediated autoimmune and complement-mediated neurodegenerative disorders. This novel therapy is formulated for IV administration and is designed to inhibit C1q and the entire classical complement pathway.

Tanruprubart (ANX005) (IV) 

Geographic atrophy

ANX007 is a clinical-stage investigational monoclonal antibody antigen-binding fragment (Fab) for the treatment of patients with complement-mediated neurodegenerative ophthalmic diseases. Formulated for IVT administration, ANX007 is designed to potently bind to C1q and inhibit activation of all downstream components of the classical complement cascade, including C3 and C5, but to not interfere with the normal function of C3 and C5 as part of other complement pathways.

Vonaprument (ANX007) (IVT)

Brain disease

Huntington's disease

Tanruprubart (ANX005) (IV)

Amyotrophic lateral sclerosis

Neurodegenerative disease

Lupus nephritis

ANX009 

Cold agglutinin disease

ANX1502

ANX105

Warm autoimmune hemolytic anemia

ANX005 is a clinical-stage investigational monoclonal antibody intended to treat patients with antibody-mediated autoimmune and complement-mediated neurodegenerative disorders. This novel therapy is formulated for IV administration and is designed to inhibit C1q and the entire classical complement pathway.

Annexon Inc.

Company Details